SAR260301
Total Payments
$34,710
Transactions
13
Doctors
6
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2017 | $34,710 | 13 | 6 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $34,710 | 13 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| SAR260301 Combination with Immunotherapy | SANOFI US SERVICES INC. | $32,943 | 0 |
| A Phase I/Ib study for the evaluation of SAR260301, administered orally in monotherapy in patients with advanced solid tumors or lymphomas, and in combination with vemurafenib in patients with unresec | GENZYME CORPORATION | $1,767 | 6 |
Top Doctors Receiving Payments for SAR260301
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Houston, TX | $32,943 | 1 |
| , M.D | Hematology & Oncology | Burr Ridge, IL | $294.43 | 2 |
| , M.D | Medical Oncology | Houston, TX | $294.43 | 2 |
| , MD PHD | Medical Oncology | Boston, MA | $294.43 | 2 |
| , M.D, PHD | Medical Oncology | Houston, TX | $294.43 | 2 |
| , M.D | Hematology & Oncology | Boston, MA | $294.43 | 2 |
| , MD | Specialist | Boston, MA | $294.43 | 2 |
Ad
Manufacturing Companies
- SANOFI US SERVICES INC. $32,943
- GENZYME CORPORATION $1,767
Product Information
- Type Drug
- Total Payments $34,710
- Total Doctors 6
- Transactions 13
About SAR260301
SAR260301 is a drug associated with $34,710 in payments to 6 healthcare providers, recorded across 13 transactions in the CMS Open Payments database. The primary manufacturer is SANOFI US SERVICES INC..
Payment data is available from 2017 to 2017. In 2017, $34,710 was paid across 13 transactions to 6 doctors.
The most common payment nature for SAR260301 is "Unspecified" ($34,710, 100.0% of total).
SAR260301 is associated with 2 research studies, including "SAR260301 Combination with Immunotherapy" ($32,943).